TRAIL/TRAIL receptor system and susceptibility to multiple sclerosis

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  López Gómez, Carlos ^a   Fernández, Óscar ^a   García León, Juan Antonio ^a   Pinto Medel, María Jesús ^a   Oliver Martos, Begoña ^a   Ortega Pinazo, Jesús ^a   Suardíaz, Margarita ^a   García Trujillo, Lucía ^a   Guijarro Castro, Cristina ^b   Benito León, Julián ^b,c,d   Prat, Isidro ^e   Varadé, Jezabel ^f   Álvarez Lafuente, Roberto ^f   Urcelay, Elena ^f   Leyva, Laura ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e Transfusion Center Blood Bank   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; GUANINE; THYMINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 4; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPANISH; TRAIL GENE; TRAILR 1 GENE; TRAILR 2 GENE; TRAILR 3 GENE; TRAILR 4 GENE; COMPARATIVE STUDY; DISEASE PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; SPAIN;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SPAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; YOUNG ADULT;

EID: 79960628020     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021766     Document Type: Article

References (34)

1. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL, (2008) The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 9: 516-26.
2. Ramagopalan SV, Knight JC, Ebers GC, (2009) Multiple sclerosis and the major histocompatibility complex. Curr Opin Neurol 2: 219-25.
3. Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thomson G, et al. (2006) Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 15: 2813-24.
4. Hillert J, Olerup O, (1993) Multiple sclerosis is associated with genes within or close to the HLA-DR-DQ subregion on a normal DR15,DQ6,Dw2 haplotype. Neurology 43: 163-8.
5. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, et al. (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357: 851-62.
6. Kristjansdottir G, Sandling JK, Bonetti A, Roos IM, Milani L, et al. (2008) Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 45: 362-9.
7. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, Broer L, Jafari N, et al. (2008) Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet 40: 1402-3.
8. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, et al. (2009) Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 18: 767-78.
9. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, et al. (2007) Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 39: 1083-91.
10. Hoffjan S, Akkad DA, (2010) The genetics of multiple sclerosis: An update. Mol Cell Probes 24: 237-43.
11. Falschlehner C, Schaefer U, Walczak H, (2009) Following TRAIL's path in the immune system. Immunology 127: 145-54.
12. Aktas O, Schulze-Topphoff U, Zipp F, (2007) The role of TRAIL/TRAIL receptors in central nervous system pathology. Front Biosci 12: 2912-21.
13. Dorr J, Bechmann I, Waiczies S, Aktas O, Walczak H, et al. (2002) Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain. J Neurosci 22: RC209.
14. Huang Y, Erdmann N, Peng H, Zhao Y, Zheng J, (2005) The role of TNF related apoptosis inducing ligand in neurodegenerative diseases. Cell Mol Immunol 2: 113-22.
15. Tang W, Wang W, Zhang Y, Liu S, Liu Y, et al. (2009) TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner. Cell Res 19: 758-67.
16. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, et al. (2000) Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356: 827-8.
17. Matysiak M, Jurewicz A, Jaskolski D, Selmaj K, (2002) TRAIL induces death of human oligodendrocytes isolated from adult brain. Brain 125: 2469-80.
18. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, et al. (2001) Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 166: 1314-9.
19. Song K, Chen Y, Goke R, Wilmen A, Seidel C, et al. (2000) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 191: 1095-104.
20. Collison A, Foster PS, Mattes J, (2009) The emerging role of TRAIL as key regulator of inflammatory responses. Clin Exp Pharmacol Physiol 36: 1049-1053.
21. Hoffmann O, Zipp F, Weber JR, (2009) Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation. J Mol Med 87: 753-63.
22. Arbour N, Rastikerdar E, McCrea E, Lapierre Y, Dorr J, et al. (2005) Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate. Mult Scler 11: 652-7.
23. Morel J, Audo R, Hahne M, Combe B, (2005) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 280: 15709-18.
24. Mi QS, Ly D, Lamhamedi-Cherradi SE, Salojin KV, Zhou L, et al. (2003) Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes 52: 1 967-75.
25. Huang WX, Huang MP, Gomes MA, Hillert J, (2000) Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 55: 928-34.
26. Lunemann JD, Waiczies S, Ehrlich S, Wendling U, Seeger B, et al. (2002) Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 168: 4881-8.
27. Kikuchi S, Miyagishi R, Fukazawa T, Yabe I, Miyazaki Y, et al. (2005) TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 167: 170-4.
28. Weber A, Wandinger KP, Mueller W, Aktas O, Wengert O, et al. (2004) Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis. J Neuroimmunol 149: 195-201.
29. Pritzker LB, Scatena M, Giachelli CM, (2004) The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 15: 2834-41.
30. Cannella B, Gaupp S, Omari KM, Raine CS, (2007) Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions. J Neuroimmunol 188: 128-37.
31. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-7.
32. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, et al. (2007) SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23: 644-5.
33. Wigginton JE, Cutler DJ, Abecasis GR, (2005) A Note on Exact Tests of Hardy-Weinberg Equilibrium. Am J Hum Genet 76: 887-883.
34. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc B 57: 289-300.